Application Nr Approved Date Route Status External Links
NDA207947 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Uptravi ® Is A Prostacyclin Receptor Agonist Indicated For The Treatment Of Pulmonary Arterial Hypertension (Pah, Who Group I) To Delay Disease Progression And Reduce The Risk Of Hospitalization For Pah. ( 1.1 ) 1.1 Pulmonary Arterial Hypertension Uptravi Is Indicated For The Treatment Of Pulmonary Arterial Hypertension (Pah, Who Group I) To Delay Disease Progression And Reduce The Risk Of Hospitalization For Pah. Effectiveness Was Established In A Long-Term Study In Pah Patients With Who Functional Class Ii-Iii Symptoms. Patients Had Idiopathic And Heritable Pah (58%), Pah Associated With Connective Tissue Disease (29%), Pah Associated With Congenital Heart Disease With Repaired Shunts (10%) [See Clinical Studies (14.1) ] .

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Selexipag SELEXIPAG ZINC3990451

Comments